CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 114 enrolled
Drug / intervention
Erythromycindrug
Likely dose
Erythromycin 125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01659619
NCT01659619Phase 2Completed
CompareCT.gov

Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis : Randomized and Prospective Study

The Catholic University of Korea·interventional·Posted Aug 8, 2012·Updated Feb 21, 2013

In Brief

A Phase 2 clinical trial evaluating Erythromycin for Subtotal Gastrectomy and Stomach Cancer. Completed, enrolled 114 participants across 1 site.

Detailed Summary

Erythromycin has a prokinetic effect through Motilin receptor. It evokes migrating motor complex with longer and stronger contraction. In patients with upper gastrointestinal bleeding, It has been shown that erythromycin could clear the stomach of blood, so visual examination could be improved. Frequent food stasis is encounted when we examine patients with subtotal gastrectomy. It is postulated that erythromycin reduce food stasis and help to improve endoscopy in these cases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubtotal Gastrectomy, Stomach Cancer
CountriesSouth Korea
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 8, 2012
Enrollment StartApr 1, 2012
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.9 years ago

Interventions

Erythromycindrug

125mg in normal saline single use infusion for 5 min.